Filing Flows › Beam Therapeutics (BEAM) › Q4 2025
Beam Therapeutics (BEAM) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Feb 24, 2026
Beam Therapeutics (BEAM) reported revenue of $114M for the fourth quarter 2025 (Q4 2025), +280% from a year earlier and up 12-fold from the quarter before. Operating margin was -15.3%, net earnings $243M (213.0% of revenue).
Beam Therapeutics, Q4 2025: revenue $114M (+280% year over year), operating margin -15.3%, net earnings $243M, operating cash flow −$83.3M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $114M | 12× | +280% |
| Operating profit | −$17.4M | — | — |
| Net earnings | $243M | — | — |
| Operating cash flow | −$83.3M | — | — |
What changed
Revenue was $114.1M in Q4 2025, up 280% year over year and up 1077% from the previous quarter.
Operating costs exceeded revenue by $17.4M, an operating margin of -15.3%. Total costs grew 1% against revenue growth of 280%. The fastest-growing cost line was General & admin (+13%). Net earnings were $243.0M. The effective tax rate was 0.0%. Non-operating items added $260.5M, 107% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$83.3M. Non-cash charges added back $5.7M of depreciation and $20.4M of share-based compensation. Working capital and other items used $352.5M. Capital expenditures of $3.7M exceeded it, leaving free cash flow of −$87.0M.
Questions
What was Beam Therapeutics' revenue in the fourth quarter 2025?
Beam Therapeutics (BEAM) reported revenue of $114M for the fourth quarter 2025 (Q4 2025), +280% from a year earlier and up 12-fold from the quarter before.
Was Beam Therapeutics profitable in the fourth quarter 2025?
Operating loss was $17.4M (-15.3% of revenue) and net earnings $243M.
Source: Beam Therapeutics 10-K on SEC EDGAR.